Liquid Biopsies for Cancer Genotyping: Coming of Age?

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Precision oncology requires comprehensive molecular profiling to identify actionable therapeutic vulnerabilities.
• Tissue biopsies are the gold standard for molecular profiling but can be limited by sample availability or quality.
• Liquid biopsies offer a minimally invasive alternative for cancer genotyping, potentially overcoming limitations of tissue biopsies.

Discussion:

• Liquid biopsies currently exhibit lower sensitivity and specificity compared to tissue biopsies for molecular profiling.
• The utility of liquid biopsies can be enhanced through novel assay development and insights gained from longitudinal monitoring.
• Integrating liquid biopsy data with clinical information is crucial for optimizing patient management in precision oncology.

Key Insights:

• Optimal molecular profiling is essential for effective precision oncology.
• Liquid biopsies show promise in complementing or overcoming limitations of tissue biopsies.
• Advancements in liquid biopsy technology are critical for expanding its role in cancer care.

Outlook:

• Future developments in liquid biopsy assays will likely improve sensitivity and specificity.
• Longitudinal profiling using liquid biopsies may provide valuable insights into treatment response and resistance.
• The expanding liquid biopsy toolbox holds significant potential for advancing personalized cancer therapies.